In a stunning move, the FDA has put clinical trials for Sarepta's gene therapy on hold due to alarming safety concerns after multiple patient deaths linked to acute liver failure. The company faces scrutiny as it navigates the fallout.
Sarepta Therapeutics is under fire as another patient succumbs to acute liver failure linked to its gene therapy trial for muscular dystrophy, adding to the recent deaths of two teenage boys.
